Full text is available at the source.
Optimizing Glioblastoma Temozolomide Chemotherapy Employing Lentiviral-based Anti-MGMT shRNA Technology
Improving glioblastoma chemotherapy with gene therapy to reduce drug resistance
AI simplified
Abstract
Inhibition of the DNA repair protein MGMT in glioblastoma cells may enhance the effectiveness of temozolomide chemotherapy.
- MGMT overexpression is associated with reduced effectiveness of temozolomide in glioblastoma treatment.
- Lentiviral delivery of anti-MGMT small hairpin RNA (shRNA) resulted in specific inhibition of MGMT expression in GBM cell lines and subcutaneous tumors.
- Xenografts with low MGMT expression showed tumor growth inhibition following temozolomide treatment, unlike those with high MGMT expression.
- Bioluminescence imaging confirmed efficient transduction of GBM xenografts with lentiviruses expressing luciferase and shRNA.
- Combination treatment of anti-MGMT shRNA and temozolomide reduced tumor size, while control shRNA with temozolomide did not.
AI simplified